Takayuki Iriyama

Dr. Takayuki Iriyama


Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2017 in The Journal of Maternal-Fetal & Neonatal Medicine
Verified
Journal Article
Closed access
AHAyako Hashimoto
Ayako Hashimoto
TITakayuki Iriyama
Takayuki Iriyama
SSSeisuke Sayama
Seisuke Sayama
TNToshio Nakayama
Toshio Nakayama
AKAtsushi Komatsu
Atsushi Komatsu
TFTomoyuki Fujii
Tomoyuki Fujii
Objective: To evaluate the potential impact of adenomyosis on the pregnancy outcomes by retrospectively investigating adenomyosis-complicated pregnancy cases. Methods: We performed a retrospective case–control study. Forty-nine singleton pregnancy cases complicated with adenomyosis were included in this study. The controls (n = 245) were singleton pregnant women without adenomyosis and were frequency matched to adenomyosis cases by age, parity, and the need for assisted reproductive technology for this conception. The incidence of obstetrical complications and delivery and neonatal outcomes were examined. Results: Patients in the adenomyosis group were significantly more likely to have a second trimester miscarriage (12.2% versus 1.2%, odds ratio (OR): 11.2, 95% confidence interval (95% CI): 2.2–71.2), preeclampsia (18.3% versus 1.2%, OR: 21.0, 95% CI: 4.8–124.5), placental malposition (14.2% versus 3.2%, OR: 4.9, 95% CI: 1.4–16.3), and preterm delivery (24.4% versus 9.3%, OR: 3.1, 95% CI: 1.2–7.2), compared with the control group. Conclusion: Adenomyosis was associated not only with an increased incidence of preterm delivery, as previously reported, but also with an increased risk of second trimester miscarriage, preeclampsia, and placental malposition, which could lead to poor perinatal outcomes.

11 March 2017 in BJOG: An International Journal of Obstetrics & Gynaecology
Verified
Journal Article
Open access
PDF file
SSS Sayama
S Sayama
NTNORIFUMI TAKEDA
NORIFUMI TAKEDA
TITakayuki Iriyama
Takayuki Iriyama
RIR Inuzuka
R Inuzuka
SMS Maemura
S Maemura
TFT Fujii
T Fujii
Objective: To investigate pregnancy outcomes, especially the risk of pregnancy‐related aortic dissection (AD), in patients with Marfan syndrome (MFS) after prophylactic aortic root replacement (ARR).Design: Retrospective case series study.Setting: Tertiary perinatal care centre at a university hospital.Population: Pregnant women fulfilling the revised Ghent nosology (2010) criteria for MFS who were managed at our institute.Methods: The pregnancy outcomes of all patients with MFS managed at our institute between 1982 and September 2016 were reviewed retrospectively based on medical records.Main outcome measures: Obstetrical management and complication including the incidence of AD throughout the peripartum period.Results: Among 22 patients (28 pregnancies) who had been managed as potential MFS or related disorders, 14 (17 pregnancies) fulfilled the revised Ghent nosology (2010) criteria for MFS and were enrolled in this study. Five patients (five pregnancies) had received ARR before conception: three (60%) developed type B aortic dissection [AD(B)] during the peripartum period, compared with only one of 10 patients (12 pregnancies) without ARR (P < 0.05, Chi‐square test).Conclusions: Our study results suggest that MFS patients after prophylactic ARR are still at high risk of AD(B) during the peripartum period. Careful pre‐pregnancy counselling and multidisciplinary care throughout the peripartum period are essential for the management of MFS, even after surgical repair of an ascending aortic aneurysm.Tweetable MFS patients after prophylactic ARR are still at high risk of type B aortic dissection during the peripartum period.

12 January 2020 in The FASEB Journal
Verified
Journal Article
Open access
PDF file
TITakayuki Iriyama
Takayuki Iriyama
WWWei Wang
Wei Wang
NPNicholas F. Parchim
Nicholas F. Parchim
SSSeisuke Sayama
Seisuke Sayama
KKKeiichi Kumasawa
Keiichi Kumasawa
RKRodney E. Kellems
Rodney E. Kellems
Recent evidence indicates that elevated placental adenosine signaling contributes to preeclampsia (PE). However, the molecular basis for the chronically enhanced placental adenosine signaling in PE remains unclear. Here, we report that hypoxia‐inducible factor‐1α (HIF‐1α) is crucial for the enhancement of placental adenosine signaling. Utilizing a pharmacologic approach to reduce placental adenosine levels, we found that enhanced adenosine underlies increased placental HIF‐1α in an angiotensin receptor type 1 receptor agonistic autoantibody (AT 1 ‐AA)‐induced mouse model of PE. Knockdown of placental HIF‐1α in vivo suppressed the accumulation of adenosine and increased ecto‐5’‐nucleotidase (CD73) and adenosine A 2B receptor (ADORA2B) in the placentas of PE mouse models induced by AT 1 ‐AA or LIGHT, a TNF superfamily cytokine (TNFSF14). Human in vitro studies using placental villous explants demonstrated that increased HIF‐1α resulting from ADORA2B activation facilitates the induction of CD73 , ADORA2B, and FLT‐1 expression. Overall, we demonstrated that (a) elevated placental HIF‐1α by AT 1 ‐AA or LIGHT upregulates CD73 and ADORA2B expression and (b) enhanced adenosine signaling through upregulated ADORA2B induces placental HIF‐1α expression, which creates a positive feedback loop that promotes FLT‐1 expression leading to disease development. Our results suggest that adenosine‐based therapy targeting the malicious cycle of placental adenosine signaling may elicit therapeutic effects on PE.

1 November 2021 in Placenta
Verified
Journal Article
Closed access
HMHaruka Matsui
Haruka Matsui
TITakayuki Iriyama
Takayuki Iriyama
SSSeisuke Sayama
Seisuke Sayama
NINaoko Inaoka
Naoko Inaoka
KSKensuke Suzuki
Kensuke Suzuki
YOYutaka Osuga
Yutaka Osuga

5 December 2021 in Journal of Obstetrics and Gynaecology Research
Verified
Journal Article
Closed access
PDF file
STSHUNSUKE TAMARU
SHUNSUKE TAMARU
SJSeung Chik Jwa
Seung Chik Jwa
YOYoshihisa Ono
Yoshihisa Ono
HSHiroyuki Seki
Hiroyuki Seki
HMHaruka Matsui
Haruka Matsui
YKYoshimasa Kamei
Yoshimasa Kamei

31 October 2022 in Cancers
Verified
Journal Article
Open access
PDF file
AKAsako Kukita
Asako Kukita
KSKenbun Sone
Kenbun Sone
SKSyuzo Kaneko
Syuzo Kaneko
EKEiryo Kawakami
Eiryo Kawakami
SOShinya Oki
Shinya Oki
YOYutaka Osuga
Yutaka Osuga
The histone methyltransferase SET domain-containing protein 8 (SETD8), which methylates histone H4 lysine 20 (H4K20) and non-histone proteins such as p53, plays key roles in human carcinogenesis. Our aim was to determine the involvement of SETD8 in endometrial cancer and its therapeutic potential and identify the downstream genes regulated by SETD8 via H4K20 methylation and the p53 signaling pathway. We examined the expression profile of SETD8 and evaluated whether SETD8 plays a critical role in the proliferation of endometrial cancer cells using small interfering RNAs (siRNAs). We identified the prognostically important genes regulated by SETD8 via H4K20 methylation and p53 signaling using chromatin immunoprecipitation sequencing, RNA sequencing, and machine learning. We confirmed that SETD8 expression was elevated in endometrial cancer tissues. Our in vitro results suggest that the suppression of SETD8 using siRNA or a selective inhibitor attenuated cell proliferation and promoted the apoptosis of endometrial cancer cells. In these cells, SETD8 regulates genes via H4K20 methylation and the p53 signaling pathway. We also identified the prognostically important genes related to apoptosis, such as those encoding KIAA1324 and TP73, in endometrial cancer. SETD8 is an important gene for carcinogenesis and progression of endometrial cancer via H4K20 methylation.